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ABSTRACT
Chagas disease (CD) is a neglected tropical highly morbid disease that can have a negative 
impact on the quality of life (QoL). The purpose of this study was to conduct an integrative 
review to analyze the QoL of patients with CD in the chronic phase of the disease, as well 
as the instruments used and the effect of different interventions. The review was carried out 
based on the criteria and recommendations of the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyzes guideline (PRISMA) using the PubMed, Scopus, Web of Science 
and Science Direct databases. An analysis of the reference list of the included articles was 
also carried out. Publications in all languages  have been included. Two independent reviewers 
selected the eligible articles and extracted the data. A total of 1,479 articles were identified, 
and after applying the inclusion criteria 18 articles were included. Four different instruments 
were used to assess QoL and the most used was the Minnesota Living with Heart Failure 
Questionnaire (MLWHFQ) [33.3% (n = 6)]. Investigations involving intervention showed 
a positive impact on the patients’ QoL, and the Environment domain had the lowest score. 
Heterogeneity of instruments and lack of methodology standardization for assessing QoL 
was observed. QoL proved to be an important indicator for the planning and monitoring of 
patients with CD, however it is suggested that the instruments for its assessment should be 
the ones recommended by the validation studies. This process will allow the comparison of 
data between investigations.
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INTRODUCTION
Chagas disease (CD) is a tropical disease caused by the protozoan Trypanosoma 
cruzi1. It is estimated that six to seven million people have CD worldwide, and they 
are located mainly in Latin American countries, with an emphasis on Argentina, 
Brazil, Mexico and Bolivia1-4. The incidence of CD is falling, with an incidence 
rate of 1.85% person-year, but we have a significant number of people living with 
the disease in the chronic form due to reduced mortality and increased survival, as 
a result of better knowledge of the natural history of the disease and improvement 
in clinical and surgical care5,6.
CD in the acute phase, is often unidentified and can progress to the chronic 
phase, also called the indeterminate form, in which the majority of patients are 
asymptomatic. The other chronic manifestations of CD are cardiac, digestive or 
both. Cardiac manifestation affects 20-30% of patients with chronic CD, and 
may present cardiomyopathy and congestive heart failure (HF)7,8. The digestive 
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manifestation involve the development of megaesophagus 
and megacolon9.
These complications may cause a decrease in the 
perception of quality of life (QoL) in individuals affected 
by the disease10,11. The QoL indicator is an important 
marker for the organization of health care in addition 
to the planning of public policies and the allocation of 
resources12,13. Because CD is a neglected disease in which 
the majority of patients attend public health services, there 
are great challenges in providing comprehensive health 
care and strengthening epidemiological and entomological 
surveillance actions14.
Therefore, studies on QoL in individuals with CD 
need to be better explored and understood in order to 
develop effective health intervention strategies15. However, 
evaluating the QoL indicator is not simple, due to the 
multidimensional characteristic of this construct, defined 
as “the individual’s perception of their position in life in the 
context of the culture and the value of a system in which 
they live and in relation to their goals, expectations, patterns, 
and concerns”16.
Thus, knowing the main aspects related to a worse 
QoL among individuals with CD will allow more specific 
interventions to improve health care. Thus, the aim of this 
study is to conduct an integrative review to analyze the 
QoL of patients with CD in the chronic phase, as well the 
instruments used for this analysis and the effect of different 
interventions. 
MATERIALS AND METHODS
The present study is an integrative review following 
the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyzes Guideline – The PRISMA Statement17. 
The review protocol was registered under the number 
CRD42020148296. The study’s hypothesis is that patients 
with chronic CD have a lower QoL. Thus, the question 
that guided this investigation was: What is the quality 
of life profile of patients with chronic Chagas disease? 
From the guiding question, the “PCO” was established: 
“P” (problem situation): Individuals with Chagas disease; 
“C” (condition): Chronic Chagas disease; “O” (Outcome): 
Quality of life. Articles that assessed the QoL of adult 
individuals with CD in the chronic phase, in all languages 
and without time limit, were considered eligible. Articles 
whose participants were in the acute phase of the disease, 
review articles, protocols, editorials, letters to the editor, 
news, comments, dissertations, and theses were excluded.
The PubMed, Scopus, Web of Science and Science 
Direct databases were used to analyze studies published 
until 02/09/2019. There was no restriction on the start 
date of the collection, since the objective was to retrieve 
the maximum number of articles, regardless of the year 
of publication. In all databases, searches were performed 
in the advanced mode. The Boolean operators “OR” and 
“AND” were used to relate the words or group of words 
in the process of elaborating the search (Supplementary 
Table S1).The data obtained from the databases were 
exported to the Rayyan QCRI virtual platform, whose 
objective was to facilitate the selection of eligible articles18. 
In the first reading, titles and abstracts were read by two 
researchers (NRB and NDQ) independently, to avoid bias 
in the selection. In case of disagreement between the two 
reviewers, a third researcher (CSC) evaluated, and by 
consensus, the final decision was made on whether or not 
to include the article.
In order to detect other publications of relevance which 
may not have been identified by the search strategy, a new 
search was performed using the bibliographic references of 
the selected articles. The restricted access studies, which 
were not fully available in the databases, were requested 
in a public library and/or formally to the corresponding 
authors via e-mail. Articles that met the inclusion criteria 
were read in full and information about the authors, 
country, study design, number of patients, morbidity of 
the clinical form of CD, and instrument used to assess 
QoL was collected.
QoL instruments
Table 1 shows the instruments that were used to assess 
QOL in the selected studies with their respective domains 
and scores. Four different QOL assessment instruments 
were identified, namely: MLWHFQ, SF-36, WHOQoLBref 
and KCCQ. Among these instruments, two are considered 
specific for individuals with HF (MLWHFQ and KCCQ) 
and two are generic (SF-36 and WHOQoLBref). The 
domains present in the instruments ranged in number from 
three to eight. The MLWHFQ is an instrument composed 
of 21 questions about the limitations often associated with 
HF. The answer scale for each question varies from 0 (zero) 
to five, where 0 represents no limitations and 5 represents 
maximum limitation19.
As for the SF-36 instrument, it has 36 questions that 
are grouped into eight domains and presents a final score 
for each domain ranging from 0 (zero) to 100, where zero 
identifies the worst general health status and 100 the best20. 
The WHOQoL-Bref has 26 questions, two of which are 
generic and the other 24 are divided into four domains: 
Physical, Psychological, Social Relations and Environment. 
Responses are scored on a five point Likert scale21. 
Finally, the KCCQ instrument consists of 15 questions, 
Rev Inst Med Trop São Paulo. 2021;63:e46
Quality of life in patients with Chagas disease and the instrument used: an integrative review
Page 3 of 12
with 23 items, organized into five domains22. All of these 
instruments provide a global assessment, without reference 
to a cutoff point for better or worse QOL.
Quality assessment and risk of bias
To assess quality and risk of bias, the Dows and Black 
tool (1998), developed and validated for randomized 
and observational studies, was used23. This tool has 
27  questions, however, for observational studies the 
instrument was adapted using only 22 questions. The 
studies were considered to be of low and moderate risk of 
bias when they did not reach 70% of the assessed domains. 
The scale developed by the Oxford Center for Evidence-
Based Medicine was used to assess the level of evidence 
and the degree of recommendation of the included studies. 
This tool allows the evaluation of each article according to 
the method used24.
Additional analysis
To analyze whether there was a change in the QoL 
according to the type of intervention study, the Delta 
Module (IΔI) was calculated, i.e., the difference in the 
QoL scores between the last assessment and the first 
(IΔI = last - baseline) was recorded.
RESULTS
A total of 1,479 articles were identified, of which 180 
were initially excluded due to duplication. After reading 
the title and abstract, 22 articles were selected for full 
reading. After analyzing these articles in full, 17 studies 
met the criteria for inclusion in the analysis. In addition, all 
references of these included articles were analyzed (n = 593) 
and after analyzing the references, one additional article 
was included in the sample, totaling 18 articles (Figure 1).
All articles were reviewed. The publications took place 
from 2006 to 2019, the majority of which were conducted in 
Brazil 94.4% (n = 17). The studies were of the observational 
and intervention type, with 50% (n = 9) being observational 
studies. Most of the articles involved patients with Chagas 
cardiomyopathy with HF. Only two studies stratified the 
clinical form of CD11,25 (Table 2).
The instrument most used by researchers to assess QoL 
of patients with CD was the specific instrument for HF, 
the Minnesota Living With Heart Failure Questionnaire 
(MLWHFQ) [33.3% (n = 6)], followed by two generic 
instruments, the Short -Form (36) (SF-36) [27.7% (n = 5)] 
and the World Health Organization Quality of Life 
(WHOQoL-Bref) [22.2% (n = 4)]19,20,21. One study used 
the specific Kansas City Cardiomyopathy Questionnaire 
(KCCQ) instrument to assess QoL in patients with HF 
[5.5% (n = 1)]22. Two studies evaluated QoL with two 
Table 1 - Instruments used to assess the quality of life in 
selected studies, their assessed domains and respective scores.
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MLWHFQ = Minnesota Living With Heart Failure Questionnaire; 
SF-36 = Short-Form; WHOQoL-Bref = World Health Organization 
Quality of Life; KCCQ = Kansas City Cardiomyopathy 
Questionnaire; QoL = Quality of Life.
Figure 1 - PRISMA Flowchart.
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instruments, one being a generic instrument (SF-36) and 
another specific for HF (MLWHFQ)26,27 (Table 2). 
Among studies that used the MLWHFQ scale, three 
were intervention studies and assessed QoL before and 
after the intervention and all showed an increase in the QoL 
scores of patients28-30. The greatest increase observed was in 
the study after the intervention with stem cells (IΔI = 29.1) 
and after transplantation of autologous cells derived from 
bone marrow (IΔI = 24.0) (Table 3)28,29.
Regarding the studies that also used the MLWHFQ scale 
Table 3 - Effect of interventions on the Quality of Life in patients with Chagas disease, by instrument.
Quality of life scores
Article Intervention T0 T1 T2 IΔI
Minnesota Living with Heart Failure Questionnaire (MLWHFQ)
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Physical capacity: 65 
(40 to 90) 
Physical aspect: 25 
(0 to 75) 
Pain: 56.5 (32 to 72) 
General health: 53.5 
(32 to 72) 
Vitality: 67.5 (35 to 75) 
Social aspect: 81.3 
(62.5 to 100) 
Emotional aspect: 66.6 
(0 to 100) 
Mental health: 88 
(44 to 48)
Physical capacity: 80 
(50 to 90) 
Physical aspect: 75 
(25 to 100) 
Pain: 72 (51 to 100) 
General health: 62 
(51 to 80) 
Vitality: 65 (50 to 90) 
Social aspect: 87.5 
(50 to 100) 
Emotional aspect: 66.6 
(0 to 100) 














Physical capacity: 68 
(19.1) 




Physical capacity: 71.3 
(18.2) 
General health: 68.1 
(21.8) 




Functional capacity: 69.3 
(20.4) 
Overall health: 69.4 
(19.4) 











T0 = Baseline; T1 = First evaluation after intervention; T2 = Second evaluation after intervention; Δ = Difference between T2 or 1 
and T0 evaluation.
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but did not assess QoL before and after the intervention, one 
assessed the QoL of participants with CD and hypertension 
and another group with CD only; the mean was similar 
between groups, 41.3 versus 37.731. Another intervention 
survey that has also assessed QoL only at baseline, showed an 
average of 3832. In the study of Vieira et al.33, it was observed 
that the QoL scores in patients without heart disease (mean 
global score: 7.2) were better than those who do not have this 
morbidity (mean global score: 31.8) (Table 4).
With regard to the studies that used the SF-36 scale, 
one of them was a prospective study and assessed QoL at 
baseline and after six years, among groups of Chagasic 
participants with and without cardiovascular adverse events. 
The results showed that among the domains evaluated, the 
summary of the mental component is that the lowest QoL 
median was found in both participants, those who developed 
adverse events (33) and those who did not (44)34. In the 
study by Pelegrino et al.35, eight domains of the instrument 
were evaluated in people with Chagas cardiomyopathy 
and people without Chagas cardiomyopathy. Participants 
without Chagas cardiomyopathy had better QoL scores in 
all assessed domains (Table 5).
Table 4 - Profile of the quality of life in people with Chagas disease assessed by specific instruments: MLWHFQ and KCCQ.
Quality of life
Article
Minnesota Living with Heart Failure Questionnaire (MLWHFQ)
Total Physical Psychological General
Mean(SD)
Dourado et al.31*
Chagas disease with SAH
41.3 (20.6) NA NA NA
Chagas disease
37.7 (21.4) NA NA NA




0 (0-10) NA NA NA
With Chagas disease
5 (0-14) NA NA NA
Total Physical Psychological General
Mean (SD)
Ritt et al.32*
38 (18) NA NA NA




31.8 (23.2) 12.4 (10.5) 7.9 (6.8) 11.5 (7.2)
Without cardiomyopathy
7.2 (9.7) 2.4 (4.2) 3.4 (4.1) 1.4 (1.9)
Chambela et al.27
Total Physical Psychological General
Mean (SD)
30.5 (27.7) NA NA NA
Kansas City Cardiomyopathy Questionnaire (KCCQ)




85 (72-94) NA NA NA
Non-Ischemic cardiomyopathy 
87 (74-96) NA NA NA
Chagasic cardiomyopathy
82 (70-92) NA NA NA
*Baseline data (cross-sectional analysis) was used.
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The study by Lima et al.36, has also used the SF-36 
butthe results are not described in the table because the 
authors only present the Δ QoL value. The mean and 
medians were used, however no feedback from the authors 
was obtained. Another intervention study showed positive 
results in which there was an increase in QoL in five of 
the eight domains, mainly in the Physical Aspect domain, 
in which the median progressed from a score of 25 to 75 
(Table 3)37.
Still referring to the SF-36 instrument, an intervention 
work was carried out in which QoL was assessed at 
baseline and after two different interventions, with one 
group undergoing ventricular stimulation and another 
atrioventricular stimulation. The domains of Functional 
Capacity and Vitality showed an increase in QoL scores, 
however for the General State domain, there was a reduction 
in scores after intervention; at baseline the mean reduced 
from 73.9 to 68.1 in the ventricular stimulation and to 69.4 
in the atrioventicular38 (Table 3).
All studies with the WHOQoL-Bref instrument used 
a sectional study design11,25,39,40. When calculating the 
mean of the Physical, Psychological, Social Relations and 
Environment domains, the results were 59.5, 62.8, 67.3, and 
55.4, respectively. In other words, the domain related to the 
environment was the one with the greatest compromise in 
QoL (Table 5).
A single study used the KCCQ instrument, which like 
MLWHFQ, is an instrument for assessing QoL specific for 
HF. In the study by Shen et al.41, the QoL of participants 
with ischemic heart disease, non-ischemic heart disease and 
Chagasic heart disease were evaluated, the median results 
were 82, 87 and 82, respectively (Table 4). Therefore, 
participants with non-ischemic heart disease had higher 
QoL scores.
Finally, the two studies that used two instruments 
presented the following results. The survey by Oliveira et al.26 
was the only study that assessed the QoL of patients with 
and without CD. The MLWHFQ evaluation showed an 
average score of 5 and zero, respectively. Regarding 
the SF-36 assessment, among the eight domains of the 
instrument, five showed higher QoL scores in participants 
without CD. That is, in the two instruments used, patients 
without Chagas disease had better QoL. The second study 
which used two instruments, presented QoL correlation 
data, so an email was sent to the authors requesting the 
mean and standard deviation of the results, and these data 
were returned and are presented in Tables 2 and 327. After 
analyzing these instruments, it was observed that there is no 
superiority between them, however, many dimensions were 
not evaluated, which hindered a more accurate analysis.
Regarding the quality of the studies evaluated, 55.5% 
(n = 10) were considered to have a low or moderate risk 
of bias. Regarding the level of evidence and degree of 
recommendation from Oxford, 50% (n = 9) were classified 
as evidence 2b, considered consistent studies, in which there 
is reasonable evidence to support this recommendation, with 
good standards of reference for decisions. The other half of 
the studies (n = 9) were classified as evidence 2c (research 
outcomes), which consists of studies with little evidence for 
the analysis of outcomes, as these are investigations with 
an observational sectional design.
DISCUSSION
In view of the main findings of this investigation, it is 
observed that studies related to QoL in patients with CD are 
relatively recent and scarce. Among the instruments used 
to assess QoL, the most used was MLWHFQ followed by 
SF-36. From the studies that used the WHOQoL-Bref, it was 
possible to identify that the Environment domain was the 
one that influenced the most the QoL in people with CD. A 
similar result was found in the study by Quintino et al.42, in 
which the Environment domain was the one that influenced 
the most a lower perception of QoL.
Regarding the study design, all intervention studies 
showed an increase in QoL after the intervention. The 
studies that showed the best results were those that 
performed bone marrow cell transplantation28,29. Despite 
presenting similar interventions, the methodological quality 
and the sample size differ. The study of Vilas Boas et al.28 
was a clinical phase 1 trial, open, uncontrolled and 
conducted with 28 participants. The second study with stem 
cells was randomized and triple blind, performed with 234 
participants29. Despite the points presented in the study by 
Vilas Boas, it was a pioneer report of great relevance for 
new perspectives in the treatment of CD, as well as for 
larger studies to occur.
In this context, it is important to note that studies that 
carry out bone marrow cell transplantation are high cost 
researches that require good hospital infrastructure and 
trained staff. The intervention carried out by Mediano et al.30 
required low financial resources, and an increase in QoL 
scores was observed. In this sense, when planning 
interventions that will be implemented in the service, 
it is important that they are viable, because, according 
to the Brazilian Consensus on CD, infected individuals 
are more vulnerable and have less access to the health 
service network4. Thus, further cost-effectiveness studies 
are needed in order to clarify the clinical and economic 
feasibility for incorporating these interventions into 
clinical practice. It is known that research in this area can 
contribute to the organization and provision of health care 
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and the implementation of actions and clinical strategies 
that influence all domains of QoL in patients with CD42,43.
As for the observational design studies, these showed 
methodological weaknesses and small sample size, and 
the studies with smaller sample sizes had 21 and 32 
participants40,33. The observational study with the largest 
sample size was the one with 361 participants11. Studies with 
small sample sizes make it difficult to generalize the results.
Regarding methodological weaknesses, the absence 
of inclusion and exclusion criteria for participants was 
identified, and some studies did not show how the sample 
size was determined26,34,35,39. Despite these points, 
observational studies have shown similar results; the 
Environment domain was the most fragile domain for QoL 
in people with CD. This finding is of great importance for 
the planning of actions focused on this domain, considering 
that it presents issues related to social determinants of 
health observed in neglected diseases such as CD. For 
Siboni et al.44 financial support programs should be among 
the main priorities of the QoL improvement programs.
In relation to the profile of the studies, it was observed 
that investigations that include patients with CD in the 
chronic phase, presenting with digestive manifestations are 
not common in the literature, as only two studies enrolled 
participants with digestive manifestations11,25. This lack of 
evidence of the QoL in patients with this clinical profile 
explains that there is a need for further investigations in 
order to organize the health service aiming at improving 
care and, consequently, the QoL of these people. The lack 
of studies in patients with digestive manifestations may be 
related to the under diagnosis of this form of CD. Another 
justification that is worth considering is the prevalence 
of the digestive form, which is lower than the cardiac 
manifestation (<10%)4, and this presents more serious 
reported complications and may influence the greater 
interest in investigations that assess the impact on QoL45. 
Due to the scarcity of research, it is also not possible to know 
which clinical form of CD has the lowest QoL.
As for the QoL instruments, it is known that there is 
no specific instrument for CD. Thus, the present work 
found four different types of instruments. Since the most 
used was MLWHFQ, this may be related to the fact that 
it is a specific instrument to assess QoL in patients with 
HF, and most of the articles included were in patients with 
Chagas cardiomyopathy and HF19. This also justifies the 
use of KCCQ in one of the studies22. A cohort study used 
the two instruments, MLWHFQ and KCCQ, to assess the 
predictive capacity of HF. The KCCQ was better to predict 
death, transplantation, and hospitalizations of patients. 
This assessment can be valuable in clinical practice for the 
monitoring of patients and to evaluate their prognosis46.
The other two instruments that were used, SF-36 and 
WHOQoL-BREF are generic and can be used regardless 
of the disease or health condition. Analyzing the four 
different instruments, MLWHFQ, KCCQ, SF-36, and 
WHOQoL-BREF enabled us to determine the most suitable 
to assess the subjective perception of people with CD in 
a way that allows comparisons with other populations, 
and the best in this category was the WHOQoL-BREF. 
Thus, the MLWHFQ and KCCQ instruments are specific 
for people with HF, i.e., not all patients with CD have 
this morbidity. For the SF-36, despite being a generic 
instrument, its domains assess QoL only related to health. 
WHOQoL-BREF on the other hand, is an instrument that 
evaluates QoL in any situation including the ones not only 
related to health, and is free and widely used.
In addition to the different instruments used to assess 
QoL, it is important to note that the participants in the 
selected studies had different CD morbidities in addition to 
other comorbidities. This fact can influence the QoL result of 
the participants. It is known that even patients with the same 
disease at similar stages can be differently evaluated with 
regard to their symptoms and limitations47. For example, in 
some of the studies included in this review, the participants 
had HF, and they know that morbidity in its advanced state 
causes greater dysfunction, and consequently worse QoL48.
The articles included in this review present some points 
that prevented a more accurate assessment of QoL in 
patients with CD: the articles did not assess all the domains 
described in the instruments; and the use of four different 
instruments hindered a grouped analysis of the different 
domains assessed.
Despite the limitations presented, the investigation 
has important findings to assist in health planning, and 
consequently making it possible to improve the QoL 
of patients with CD: the need for investments in more 
robust studies that will assess the cost-effectiveness of 
interventions that improve QoL; the need for studies with 
CD individuals with digestive manifestations or with the 
indeterminate form, as there is a lack of evidence of QoL 
in these patients; and the need to standardize the use of an 
instrument for assessing QoL considering the domains and 
summary measures proposed by each instrument.
CONCLUSION
From the findings of this review, it can be concluded that 
the QoL of people with CD is still a challenge, and there 
is no superiority between the instruments used, thus their 
application will depend on the goals of each research. It was 
observed that interventions in patients with CD are valid and 
have a positive impact on the QoL of individuals with this 
Baldoni et al.
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disease, and that the Environment domain has the lowest 
score for QoL. It is suggested that in investigations involving 
the QoL assessment, the instruments should be the ones 
used in the instrument’s validation studies. This process 
will allow the comparison between investigations. Thus, 
the QoL profile in individuals with CD is more accurately 
identified, and these indicators can be important for 
organizing the care of patients with CD and consequently, 
positively impact the QoL.
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